Insmed reported Q2 2026 revenues of $425.5M, with BRINSUPRI at $309.2M. It raised 2026 BRINSUPRI guidance to $1.25B-$1.40B and lifted peak revenue estimates for its lead programs to over $14B.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07743996 |
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study |
RECRUITING | |
| NCT07723872 |
Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease |
RECRUITING | |
| NCT07722507 |
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis |
NOT_YET_RECRUITING | |
| NCT07683728 |
A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA) |
RECRUITING | |
| NCT06951217 |
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) |
RECRUITING | PHASE2 |
| NCT06855329 |
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis |
RECRUITING | |
| NCT06329401 |
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06238622 |
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast |
RECRUITING | PHASE3 |
| NCT05943535 |
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) |
RECRUITING | PHASE3 |
| NCT05241275 |
Xenon MRI and Progressive ILD |
ACTIVE_NOT_RECRUITING | PHASE2 |
